Mexico’s Cofepris, the national health regulator, granted the world’s first sanitary registration for an RNA-based biofungicide on August 12, 2026. This unprecedented move, paired with a US$100 million plant investment in Mexico City by GreenLight Biosciences, signals a profound shift in national agricultural policy. It establishes a precedent that could force other Latin American nations to surrender control over their food systems.
The product targets powdery mildew in grapes, caused by Erysiphe necator. Its mechanism, described by Mexican regulators, “turns off the fungus’s gene” needed for survival. Officials claim the RNA acts only on the target fungus and degrades naturally in soil, water, and fruit. Cofepris approved the product in coordination with Senasica and Semarnat, national agricultural and environmental agencies.
GreenLight Biosciences founder and CEO Andrey Zarur announced the manufacturing plans alongside the approval. This registration marks a significant reorientation in how regulators and growers approach crop protection. It clearly indicates Mexico's openness to biotech innovation in agriculture, provided the science aligns with global standards.
Eroding National Control
The approval is not an isolated national decision. It is framed as a precedent designed to encourage other transnational companies to introduce similar products across the region. This move will pressure other Latin American regulators to develop RNA-based crop-protection frameworks, rather than waiting for independent national assessments. Argentina, Brazil, and Chile, all with large, export-driven farm sectors, could face intense pressure to fast-track similar approvals. This effectively transfers national regulatory autonomy to a supranational agenda.
The U.S. EPA registered the first sprayable RNA pesticide in 2023. This earlier action by a major Western regulator underscores the coordinated, international push for this specific technology. National borders are increasingly irrelevant in the face of such synchronized regulatory shifts.
The Cost to Local Autonomy
Proponents claim the RNA biofungicide could help growers maintain high yields while lowering environmental impact. They also suggest local production in Mexico City could support local supply chains and local jobs. Yet, these “local benefits” are tied to a US$100 million investment by a global corporation, not organic national development. The promise of “shorter distance between production and application for growers across North and Central America” further reveals the transnational scope of this initiative.
Conventional chemical fungicides, often produced by established national industries, are described as broad-spectrum tools. They can harm beneficial fungi, disrupt soil ecosystems, and leave residues that “regulators and consumers increasingly frown upon.” This framing pathologizes existing national practices, paving the way for the new, globally-driven biotech solutions. The shift benefits supranational institutions and large corporations, not necessarily the native working class farmer.
The specific commercial product name remains unconfirmed in available reporting. This lack of transparency further obscures the true beneficiaries of this regulatory capture.